C difficile risk
Oral Bioavailability


600mg PO/IV q12h

General Information

  • Targeted or empiric therapy for gram positive infections including skin and soft tissue, and pneumonia.

  • Bacteriostatic, do not use 1st line for suspected/confirmed invasive bloodstream infections.

  • Covers MRSA and VRE.

CBC at least once/week

Visual testing for therapy >3 months or if symptoms develop on therapy.

  • Rash

  • Elevated liver enzymes

  • Lactic acidosis

  • Myelosuppression esp. thrombocytopenia (usually with >2weeks therapy)- reversible

  • Serotonin syndrome (in combination w/ other serotonergic agents)

  • Peripheral/optic neuropathy with prolonged courses

SSRI and other serotonergics/MAOIs - Increased risk of serotonin syndrome.

Rifampin decreases linezolid levels.

Antimicrobial class: Oxazolidinone

Pregnancy category: C

Average serum half life: 5 hours

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.